Zacks Investment Research | Sep 19, 2017 08:58AM ET
Varian Medical Systems (NYSE:VAR) recently announced the release of an FDA-approved treatment planning software — Eclipse 15.5. This will help clinicians treat with more accuracy and efficiency.
Eclipse 15.5 also provides treatment planning support for Varian's HyperArc Oncology Systems (HDRT) for efficient and automated delivery of complex stereotactic radiosurgery. HyperArc HDRT is a new type of radiosurgery treatment. Eclipse 15.5 offers Graphics Processing Unit (GPU) support to help physicians optimize and speedily calculate the dose.
Eclipse 15.5 features Multi-criteria optimization (MCO) which allows clinicians to explore the application of different clinical criteria. According to the company, According to the company, MCO focuses on finding the optimal plan faster for a given patient with minimal trial and error iterations.
In the last reported third quarter, Varian Medical’s revenues declined 1.9% at Oncology Systems. The company is consistently trying to turn around its Oncology Systems business.. Apart from the latest development, the company recently announced FDA clearance for its revolutionary Halcyon product. The company received orders from 10 countries for the system. In North America, the company signed an agreement with PetCure Oncology to bring an unprecedented level of care to pets suffering from cancer.
According to a report by Markets And Markets, the global oncology information system market is expected to reach a worth of $2.6 billion by 2019 at a CAGR of 8.5% from 2014 to 2019. Considering the huge potential of the market, we believe the latest development is a strategic fit.
Over the past three months, Varian Medical has outperformed the broader Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.